ProCE Banner Activity

Cardiotoxicity of CPX-351 vs 7+3 in Previously Untreated High-Risk or Secondary AML: Post Hoc Analysis of a Pivotal Phase III Trial

Conference Coverage
Slideset

CPX-351 was associated with less cardiotoxicity than standard 7+3 chemotherapy in older patients with newly diagnosed high-risk or secondary AML in this post hoc analysis of a pivotal phase III trial.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis